drugset / Trial / NCT03381430
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Unknown
50 enrolled
Qilu Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collabChina-Japan Friendship Hospital · collabChinese PLA General Hospital · collabPeking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
To explore the survival benefit of the gefitinib combined with radiotherapy as adjuvant therapy for completely resected patients with Pathological stage IIIA-N2 NSCLC harbouring sensitive mutations of EGFR.
Timeline
- Start
- 2018-06
- Primary completion
- 2023-03
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 250 mg | Oral |